US Orphan Drug Market Report, Size, Share and Forecast 2026–2033: Half of 2025's Novel Approvals Were Orphan Drugs and Carried a Fifth of the Evidence

Overview: the premise is exact, and the exactness is the least interesting part

The FDA's Center for Drug Evaluation and Research approved 46 novel drugs in 2025 — products never before approved or marketed in the United States — of which 34 were new molecular entities and 12 were new therapeutic biologics. Exactly 23 (50.0 per cent) received Orphan Drug Designation. Adding the Center for Biologics Evaluation and Research, the combined novel-approval count for the year was 58; CDER's total approvals across novel and non-novel products were 123.

So the premise is right on both halves. But a count is not a market. What follows is the arithmetic that turns 23 into revenue, and it starts with a number almost nobody quotes: the evidence base underneath those 23 approvals was 5,001 pivotal-trial participants — 19.2 per cent of the roughly 26,000 participants supporting all 46 approvals, at a mean of 217 and a median of 114 patients per orphan programme.

The 2025 orphan cohort, by evidence base

All 23 orphan-designated novel approvals are listed below in ascending order of the patients in the pivotal programme that supported approval. The right-hand column is the point: nine of the twenty-three were approved on a data set of a hundred patients or fewer, and the largest single programme (1,322) is larger than the smallest nine combined.

The distribution is not a smooth curve. Nine of 23 (39.1 per cent) were approved on 100 patients or fewer; twelve sit between 101 and 500; two exceed 500. Summed, all 23 orphan programmes together enrolled 5,001 patients. For comparison, three non-orphan programmes in the same year — Enflonsia at 4,510, Journavx at 2,447 and Lerochol at 2,322 — enrolled 9,279, or 1.86 times the entire orphan cohort.

The five things the 46 / 23 split does not tell you

1. Half the approvals carried a fifth of the evidence

Orphan drugs were 50.0 per cent of the year's novel approvals and 19.2 per cent of its pivotal evidence. That is not a criticism of the agency or the sponsors; it is the arithmetic of small populations, and it is why the cohort's revenue has to be understood as price multiplied by a small number of treated patients, discounted by how hard those patients are to find and keep.

2. Price is the market, and price stalled in 2025

ICER and West Health's second annual Launch Price and Access Report puts the median annual net launch price at USD 257,000 in 2025 — up 35 per cent on USD 190,000 in 2022, a compound 10.59 per cent a year, but down 2 per cent on 2024, the first decline in the series. About one in four 2025 launches priced above USD 500,000 a year net, and a further 34 per cent between USD 200,000 and USD 500,000, so roughly three launches in five cleared USD 200,000. Reuters' separate list-price series put the 2024 median above USD 370,000, with oncology and rare-disease therapies above USD 400,000 on the Tufts Medical Center specialty-drug analysis. A market whose unit price is a quarter of a million dollars a year per patient and no longer rising is a market whose growth must come from somewhere other than price.

3. The binding constraint is the fill, not the approval

In the first year after approval, only about one third of outpatient prescriptions were filled within 30 days of being written. Fill rates were 51 per cent for commercial patients, 42 per cent for Medicaid and 20 per cent for Medicare; non-coverage rejections ran at 24 per cent commercial, 20 per cent Medicaid and 58 per cent Medicare. Applied to the median net price, a filled year of therapy is worth USD 257,000 and a written prescription is worth USD 85,658. For a drug with twelve pivotal patients, a single non-coverage denial is not a rounding error; it is a fifth of the trial.

4. Policy moved in the orphan drug's favour at exactly the moment price stopped cooperating

The Working Families Tax Cuts Act (Public Law 119-21), section 71203, widened the Medicare Drug Price Negotiation orphan exclusion. Under the earlier test, only a drug designated for one rare disease, with all approved indications in that single rare disease, was excluded from negotiation. The new test excludes a product if all of its approved indications are for one or more rare diseases, however many such indications it accumulates. CMS addressed the exclusion in its final guidance for the initial price applicability year 2028, published 30 September 2025 — where the test the guidance restated was still the single-designation one. That gap between statute and guidance is treated as unresolved in the regulatory chapter, and it is the one open question that bears directly on the value of a stacked rare label.

The commercial consequence is that the most valuable act available to an orphan sponsor between now and 2033 is not a price increase. It is a second rare-disease indication. A follow-on orphan label converts a product from negotiable once it matures into permanently outside the negotiation, and the base rate for follow-on activity is already high: on the Tufts analysis of 947 specialty drug-indication pairs, 188 (19.9 per cent) carried at least one follow-on indication, averaging 1.7 per product.

5. The cohort is fragmented by sponsor and concentrated by class

Twenty-three approvals came from something close to twenty-three separate sponsors — Verastem, Nuvation, Chimerix, Kalvista, SpringWorks, Deciphera, Kura, Crinetics, Stealth, Omeros, Arrowhead, Ionis, PTC, Lenz, Akeso, Medexus, Genzyme, Sanofi, Johnson & Johnson, and others. That is the fragmented half of the market. The concentrated half is therapeutic class: three of the twenty-three are hereditary angioedema drugs (Andembry and Dawnzera for prophylaxis, Ekterly for acute attacks) and eight are oncology, including two separate HER2-directed non-small cell lung cancer agents in the same year (Hyrnuo in November, Hernexeos in August).

The market, and how the number was built

This report sizes US revenue from FDA orphan-designated medicines, measured in net revenue, base year 2025.

The base is derived rather than observed, and the derivation is stated so a reader can substitute their own inputs. US specialty drug spending was approximately USD 263 billion in 2024 (Tufts Medical Center, Health Affairs Scholar, February 2026, citing IQVIA Institute data). Orphan-designated products accounted for 55 per cent of specialty drug-indication pairs on the same analysis. Applying that share to specialty spend gives USD 144.65 billion for 2024; growing at 9.0 per cent — the rate at which specialty spending has been compounding as it rose from 47 per cent of pharmaceutical spending in 2019 to 54 per cent in 2024 — gives a 2025 base of USD 157.7 billion.

The base case composes to 1.0097 x 1.015 x 1.020 = 1.0454. Note what is not in it: price growth of the kind the 2022-25 series delivered. If the median net launch price resumes compounding at anything near its 10.59 per cent three-year rate, this forecast is far too low. If orphan designations keep arriving at 50 per cent of approvals but the orphan exclusion is narrowed again, it is too high.

Market segmentation: five ways to cut this market, and only one that moves the forecast

A segmentation earns its place in a report only if it either reconciles to a published total or changes a decision. Four of the five cuts below are descriptive, and every one of them reconciles to the same 23 approvals and the same 5,001 pivotal patients. The fifth, by indication breadth, is the only one that touches the forecast, because Public Law 119-21 turned an indication count into a pricing instrument.

Cut one — therapeutic area: oncology is a third of the approvals and a different third of the spend

The last column is the check that makes this cut usable. The eight oncology programmes are six oral and two injectable, and the cohort-wide oral count of twelve only closes if haematology, metabolic, HAE, cardiology, endocrinology and respiratory contribute exactly the six orals they list. They do, and the injectables close at eleven the same way. Two classifications built independently — therapeutic area and route of administration — therefore reconcile to the same figures, which is the minimum condition before either is used to price anything.

The commercial reading is not the approval count. Oncology is 34.8 per cent of the cohort and its eight programmes are the most contested in the year, because biomarker-defined oncology is the one segment where the prescribing population is large enough for a second entrant to matter — a point the competitive chapter develops against this library's acute myeloid leukemia and CAR-T cell therapy work, where the same crowding has already been priced. Metabolic and genetic disease is a different 17.4 per cent: Forzinity, Kygevvi, Redemplo and Sephience average 65.75 patients per pivotal programme, the deepest end of the ultra-rare bucket, and the segment where a population the size of malignant infantile osteopetrosis — measured in the low hundreds nationally — sets the revenue ceiling rather than competition does.

Cut two — route of administration, which is the price

Those averages are list prices from 108 non-oncology orphan launches between 2015 and 2024, so they are not directly comparable with the net figures used elsewhere in this report. The distinction matters more than it looks. The 2025 median annual list price was USD 293,000 and the median net price was USD 257,000, per ICER and West Health. A cohort that is 52.2 per cent oral, with a dozen programmes under 500 patients and nine under 100, should have a list median below the USD 314,000 oral average — and USD 293,000 is exactly that. Read against the route gradient, the 2025 price point looks less like discipline than like arithmetic, which is the mix hypothesis stated qualitatively in the technology chapter and quantified here.

Cut three — evidence scale, which sums to the whole cohort

601 plus 2,508 plus 1,892 is 5,001 — the cohort total quoted at the top of this report reconstructed from the bands rather than asserted. The bands are also the most concentrated fact in the analysis: the nine ultra-rare programmes enrolled 12.0 per cent of the cohort's pivotal evidence, the middle band 50.1 per cent, and the two programmes above 500 patients 37.8 per cent. That last figure is 8.7 per cent of the approvals carrying more than a third of the evidence. The nine smallest programmes together enrolled 601 patients, fewer than Jascayd alone.

Cut four — payer channel, where the segment meets the price

At the median net price a filled patient-year is worth USD 257,000 and a written prescription is worth USD 85,658, so this is a segmentation of revenue destruction rather than of revenue. It belongs in a segmentation chapter because the cohort's therapeutic mix maps onto it with unusual precision: acromegaly, generalised myasthenia gravis, idiopathic pulmonary fibrosis, multiple myeloma and obstructive hypertrophic cardiomyopathy are Medicare-weighted populations, and between them they carry five of the cohort's larger programmes. A therapeutic-area segmentation without a channel segmentation therefore overstates revenue in exactly the four segments that sit outside oncology — which is the opposite of the intuitive error, and the reason both cuts are published together.

Cut five — indication breadth, the only cut that changes the forecast

Before section 71203, an orphan product's value depended on staying narrow: a second, broader indication could cost it the Medicare negotiation exclusion. After it, the exclusion attaches to a product all of whose approved indications are rare, however many that is. The market therefore now segments on indication breadth in a way that has nothing to do with science, and margin now follows the middle row of this table.

The base rate for the middle row is already high and rising: 188 of 947 specialty drug-indication pairs, 19.9 per cent, carried at least one follow-on indication, at a mean of 1.7 per product. Expect the mean to climb, because the policy now pays for the second label in a way it did not in 2024.

And the cut this report will not publish: revenue by segment

The observable segmentation stops at counts, route and price, and the reason is arithmetic rather than discretion. At the 2025 median net price of USD 257,000, a USD 157.7 billion market implies 613,619 treated patient-years. Allocating that base across therapeutic areas requires prevalence by indication, which no public source publishes consistently for this cohort, and the cohort's own pivotal figures are trial enrolments rather than populations. A revenue-by-therapeutic-area table here would be a set of assumptions wearing a data table's clothes. What this report publishes instead is the unit spine — 613,619 patient-years — alongside the price anchors by route and the count shares, so that a reader with their own prevalence assumptions can build the split and see precisely which input they own. That is the honest trade, and it is why the volume fields behind this page are empty rather than filled with a unit series nobody disclosed.

One caution the segmentation forces, and it points against this report's own base case. ICER's 2025 mix table has the share of approvals falling into every high-price category moving down: gene and cell therapies at 9 per cent against 10 to 13 per cent in 2022-24, biologics at 40 per cent against 50 to 58 per cent, orphan products at 55 per cent against 60 per cent, and ultra-rare drugs at 11 per cent against 18 to 25 per cent. That is not the same numerator as CDER's 50.0 per cent and the two should never be netted against each other, but the direction is single and it is unfavourable: the orphan share of approvals fell in 2025. This report's base case has that share rising from 50.0 to 54.0 per cent by 2033, at 0.97 points a year. One down year does not overturn a nine-year assumption of modest recovery, but a second year in the same direction would, and that is now the cheapest available test of whether the forecast is on the right side of its own central input.

What this report is not

It is not a count of approvals. It is not a projection built on pipeline designations, because the relationship between designation and approval is loose in both directions — the FDA itself footnotes that not all drugs for rare diseases receive designation, which is why Reuters' analysis found 72 per cent of 2024's new drugs were for orphan diseases while CDER counted exactly 50 per cent with orphan designation in 2025. Both numbers are correct; they measure different things. Nor is it a claim that the orphan market is immune to price pressure — the 2 per cent net-price decline in 2025 is the first evidence in this series that it is not.

The chapters that follow take the value chain apart where value is actually captured, examine the technology-price relationship inside the cohort, set out the regulatory stack including Public Law 119-21, quantify the investment case and its exit route, and state the risks and the specific observations that would prove this analysis wrong.

Table of Contents

1. Overview: the premise is exact, and the exactness is the least interesting part
2. Contents
3. Competitive landscape: twenty-three sponsors, eight classes
4. Value chain: where the money is actually captured
5. Investment activity: the cheapest evidence in the industry
6. Technology and innovation: the route of administration is the price
7. Market risk: five things that break this forecast
8. Regulatory landscape: the designation, the clock and Public Law 119-21

Competitive Landscape

Competitive landscape: twenty-three sponsors, eight classes

The orphan market’s competitive structure is two markets stacked. The approval layer is almost atomised: 23 orphan approvals in 2025 came from something close to 23 distinct sponsors, most of them single-asset or few-asset companies. The revenue layer is concentrated: a small number of franchises carry the majority of orphan spending, because revenue follows persistence and persistence follows distribution. Any analysis that reads the approval count as a measure of competition gets the answer backwards.

The 2025 sponsor map

Class concentration is sharper than company concentration

Three of the twenty-three are hereditary angioedema products — Dawnzera and Andembry for prophylaxis and Ekterly for acute attacks — approved within nine weeks of each other (16 June, 3 July, 21 August). Three is not a crowded class in absolute terms, but HAE is a small prevalent population that already had multiple effective therapies, so 2025 added three mechanisms to a market whose treated population does not grow by three. The same pattern appears in oncology: eight of the twenty-three are cancer indications (Avmapki Fakzynja, Gomekli, Hyrnuo, Ibtrozi, Komzifti, Lynozyfic, Modeyso, penpulimab), including three non-small cell lung cancer approvals in one year across the full 46 — Hyrnuo (19 November, orphan), Hernexeos (8 August, non-orphan) and Zegfrovy (2 July, non-orphan) — all biomarker-defined and all competing for the same prescribing oncologists.

The two structural moats, and neither is the molecule

Moat one: the fill. With one third of prescriptions filled within 30 days and Medicare non-coverage rejection at 58 per cent, the operator that can convert a written prescription into a filled, persisted patient-year owns the economics. That capability is built from hub services, benefits investigation, prior-authorisation capacity and copay infrastructure. It is replicable in principle and slow in practice, and it is why large-cap rare franchises trade at a premium to their pipeline.

Moat two: the second orphan indication. Section 71203 of Public Law 119-21 excludes from Medicare negotiation any product all of whose approved indications are rare. A single-indication orphan will eventually face negotiation; a multi-indication, all-rare product does not. So the follow-on indication is simultaneously a revenue expansion and a permanent pricing shield, and the base rate for follow-on activity is already high — 188 of 947 specialty drug-indication pairs (19.9 per cent) carried one, at a mean of 1.7 per product. Expect that mean to rise.

Where competition actually shows up in price

First-in-indication positioning is worth real money. Across 108 non-oncology orphan launches from 2015 to 2024, first-in-indication products carried an expected USD 254,280 price premium over second-or-later entrants. Strip out the ultra-rare products — those under 1,000 US patients — and the premium collapses to USD 82,813, a ratio of 3.07 to 1. The reading is unambiguous: the first-mover advantage in orphan drugs is mostly a small-population phenomenon, not a general reward for innovation. The 2025 cohort’s nine sub-100-patient approvals are therefore sitting on the most defensible prices in the year and the smallest addressable revenue, while its twelve 101-500 programmes are in the zone where a second entrant actually costs money.

The ultra-rare end of that spectrum is worth quantifying, because it is where the premium and the ceiling meet. Forzinity’s twelve-patient programme in Barth syndrome sits in a prevalent population of the same order as malignant infantile osteopetrosis — a disease whose entire US population is measured in the low hundreds, so that the competitive question is not who else will enter but whether the treated population can pay back a development programme at all. Nothing in the 2025 record shows a competitor moving on any of the five smallest indications.

Reading the cohort competitively

• Most defensible: Forzinity (Barth syndrome, 12 patients), Kygevvi (TK2 deficiency, 78), Redemplo (familial chylomicronemia, 75), Yartemlea (HSCT-TMA, 47), Avmapki Fakzynja (KRAS-mutated LGSOC, 57). No competitor is coming, and the revenue ceiling is set by prevalence, not by share.
• Most contested: Hyrnuo and Ibtrozi (NSCLC, each facing same-year or prior entrants), Ekterly, Dawnzera and Andembry (HAE), Komzifti (NPM1-mutant AML, an indication this library covers in its acute myeloid leukemia report, alongside Grafapex in transplant and Lynozyfic in myeloma), Palsonify (acromegaly, where injectable somatostatin analogues hold the base).
• Largest revenue exposure: Jascayd (IPF, 1,322-patient programme) and Grafapex (HSCT preparative, 570) are the only two programmes with evidence bases big enough to support a broad commercial footprint — which is exactly why they sit in classes with existing incumbents rather than in white space.

Myeloma is the clearest example of how fast that white space closes. Lynozyfic reached approval on an 80-patient programme in a line with four or more prior therapies; the same disease is where BCMA-directed CAR-T cell therapy is already established, which means a bispecific arriving in 2025 enters a class with a priced incumbent rather than a vacuum. That is the pattern to expect from here: the approval layer keeps atomising while the classes it lands in keep consolidating around whoever got there first.

The competitive conclusion is that the 2025 cohort will be remembered not for 23 approvals but for what those 23 approvals reveal: the industry has industrialised the production of very small, very expensive, very defensible products — and has not solved the problem of getting them filled.

Value Chain

Value chain: where the money is actually captured

The orphan value chain looks like the conventional pharmaceutical chain — discovery, development, approval, manufacturing, distribution, reimbursement — and behaves nothing like it, because the constraint at each stage is a different one. In a primary-care market the binding constraint is demand. In an orphan market it is identification, then authorisation. Nothing else. Identification is not a metaphor: it runs through the diagnostic and laboratory layer, which this library sizes separately in its clinical laboratory services and diagnostic tests reports, and the pace at which a rare disease can be diagnosed upstream sets the ceiling on how fast any therapy below it can be filled.

The five stages, and what each one actually costs

Stage one: designation is an option, not a market

Orphan designation buys seven years of market exclusivity, a waiver of the prescription drug user fee, a tax credit for qualified clinical testing, and access to protocol assistance — the four incentives the FDA’s designation page sets out. None of those is revenue. What the designation does is make a programme financeable against a very small patient population, because the exclusivity period protects the price for long enough that a few hundred patients can carry the development cost. That is the entire economic logic, and it is why the 2025 cohort’s median programme size of 114 patients and its median net price of USD 257,000 are not independent facts — they are the same fact.

Stage two: development is where the orphan model is cheapest

The cohort’s evidence base is the most under-appreciated input in the market. Forzinity was approved on 12 patients; Yartemlea on 47; Avmapki Fakzynja on 57. At the other end, Jascayd was approved on 1,322 and Grafapex on 570. The cost of a pivotal programme for the small half of this cohort is not a meaningful fraction of a conventional Phase III; it is closer to a large Phase II. That changes the shape of the development business — a virtual sponsor with one asset and a contract research organisation can reach an approval — and it changes the failure economics, because roughly one application in five received a complete response letter rather than an approval.

Stage three: approval speed is a solved problem, and therefore not a moat

Thirty-three of forty-six (71.7 per cent) used at least one expedited programme; 18 used fast track (39.1 per cent), 15 breakthrough therapy (32.6 per cent), 21 priority review (45.7 per cent) and 11 accelerated approval (23.9 per cent). Ninety-six per cent met their PDUFA goal date and 84.8 per cent cleared on the first cycle. When almost everyone gets an expedited review and almost everyone clears first cycle, regulatory speed stops being a differentiator and becomes a baseline cost of competing. The differentiator migrates downstream to the two stages that are not solved.

Stage four: distribution is where a USD 257,000 price is either collected or lost

This is the stage that decides the market. In the first post-approval year, only about one third of outpatient prescriptions were filled within 30 days of being written, and the payer gradient is stark: 51 per cent commercial, 42 per cent Medicaid, 20 per cent Medicare, with non-coverage rejection at 58 per cent in Medicare against 24 per cent commercial. For an orphan drug that gradient is not a collection problem, it is a population problem — the Medicare-heavy rare-disease cohorts (acromegaly, generalised myasthenia gravis, idiopathic pulmonary fibrosis, multiple myeloma, hypertrophic cardiomyopathy) are precisely the ones where half or more of the written prescriptions never become a filled year. The value chain therefore bids for hub services, field reimbursement teams, nurse educators and patient-support infrastructure, none of which appears on a molecule patent and all of which shows up in the launch curve.

Stage five: reimbursement duration, not price, is the compounding variable

At USD 257,000 a year, one patient retained for eight years is worth more than two patients retained for three. The 2025 cohort’s mix matters here: twelve of the twenty-three orphan approvals are oral solids (Ekterly, Sephience, Palsonify, Myqorzo, Jascayd, Komzifti, Modeyso, Hyrnuo, Ibtrozi, Wayrilz, Avmapki Fakzynja, Gomekli), a chronic-dose, self-administered profile, while eleven are injectables, infusions or powders, which carry higher per-patient prices but heavier site-of-care and administration costs. Chronic oral dosing is the cheaper product to distribute and the harder price to defend.

What Public Law 119-21 did to the tail of this chain

Before section 71203, the orphan exclusion from Medicare negotiation applied narrowly: a single rare-disease designation with all indications inside it. That created a live strategic trade-off — add a second, broader indication and the exclusion was lost. The widened test in Public Law 119-21 removes the trade-off. A product whose approved indications are all rare stays outside negotiation no matter how many of them it accumulates. In value-chain terms the terminal value of a designated asset is no longer capped by a negotiation clock, and the rational response is to keep stacking rare indications rather than to broaden into common disease. That is a change in where the industry will spend its development dollars, and it is the most consequential thing in this report — with the caveat that the IPAY 2028 guidance still states the narrow test, so the tail of this chain is worth more under the statute than under the guidance as written.

Investment Activity

Investment activity: the cheapest evidence in the industry

The investment case for orphan assets rests on three numbers that compound: the cost of the pivotal programme, the price at approval, and the duration of the exclusivity window. On all three, the 2025 cohort improved the case — and on a fourth, the fill rate, it did not.

1. The cost of evidence

A median pivotal programme of 114 patients across 23 approvals, with nine of them under 100 patients, means the capital required to reach a US approval in an orphan indication is a fraction of what a common-disease programme costs. That is the structural reason the approval layer has atomised into single-asset sponsors: the barrier to a first approval is low enough for a company with one asset and a contract research organisation. It is also why 23 approvals arrived from something close to 23 companies rather than from five.

2. The price at approval

The ICER and West Health launch price series puts the median annual net launch price at USD 257,000 in 2025 — a median list price of USD 293,000 — with roughly a quarter of launches above USD 500,000 and a further 34 per cent between USD 200,000 and USD 500,000. Price is the second multiplier, and it is mechanically linked to the first: the smaller the population, the higher the price a payer will tolerate, and the data bear that out — first-in-indication products in ultra-rare indications command a premium over later entrants that is 3.07 times the premium available outside the ultra-rare band.

3. The exclusivity window, now with a policy floor

Seven years of orphan exclusivity plus the widened negotiation exclusion in section 71203 of Public Law 119-21. The second of those is new in 2025 and it is worth more than the first, because it does not expire on a calendar — it expires only if the product adds a non-rare indication or the statute is narrowed. For a sponsor choosing between a broad label and a stacked rare-disease label, the 2025 policy change makes the stacked rare label the higher-net-present-value choice. How firmly that floor is in place is not settled: the IPAY 2028 CMS guidance still describes the narrower single-designation test, and the regulatory chapter treats the difference between statute and guidance as an open question rather than a resolved one. An investment case that leans on this floor should size how much of the terminal value depends on which reading survives.

4. The fill rate, which cuts the other way

One third of outpatient prescriptions filled within 30 days in the first post-approval year, 20 per cent Medicare fill, 58 per cent Medicare non-coverage rejection. What that does to an investment model is stretch the launch curve — revenue arrives later than the label suggests, and the discount rate does more damage than the price does. At a median net price of USD 257,000, the difference between a 33.3 per cent fill and a 51 per cent commercial-only fill is USD 45,442 per prescription written (USD 85,658 against USD 131,100). No pricing negotiation in the period covered by this report is worth as much as that gap.

Where the capital is going, and why

• Into evidence, because it is cheap. Small-programme approvals keep the cost of a first asset low, which keeps the population of fundable single-asset companies large. This is why the approval layer stays fragmented even as the revenue layer consolidates.
• Into the distribution layer, because it is the constraint. Hub services, patient services, specialty pharmacy relationships and reimbursement infrastructure are where a USD 257,000 price becomes cash. The buyer of a single-asset orphan company is, in most cases, buying the label and bolting it onto an existing distribution machine.
• Into follow-on rare indications, because the policy now pays for them. Section 71203 converts the second rare indication from a nice-to-have into a permanent exclusion from Medicare negotiation. Expect the 19.9 per cent follow-on rate on specialty drug-indication pairs to rise, and the mean of 1.7 follow-ons per product with it. The oncology half of this cohort is where that arithmetic is already visible — NPM1-mutant AML and multiple myeloma are both indications this library sizes separately, in its acute myeloid leukemia and CAR-T cell therapy reports, and in both the follow-on label rather than the first approval is what carries the revenue.

The inference this report will not dress up as fact

There is no disclosed orphan-drug transaction price in the 2025 record that would let this report price the cohort’s assets directly. The inference drawn here — that the exit route for a single-asset orphan sponsor is acquisition into a balance sheet that already owns a distribution layer — is an inference from structure (23 sponsors, 23 approvals, one third fill), not from a disclosed deal. A single disclosed acquisition at a price materially above the cohort’s implied average would confirm it; one materially below would falsify it. This is stated as a falsifier in the risk chapter rather than presented as an established fact.

The base case, in investment terms

The market grows from USD 157.7 billion in 2025 to USD 224.9 billion in 2033 at 4.54 per cent, composed of orphan share of approvals rising from 50.0 to 54.0 per cent (+0.97 per cent a year), treated patients growing 1.5 per cent a year, and net price growing 2.0 per cent a year. The low case — USD 170.7 billion at 1.00 per cent — is what happens if the 2025 net-price decline is the start of a trend rather than an interruption. The high case — USD 264.3 billion at 6.67 per cent — is what happens if price growth re-accelerates even partially toward its 2022-25 rate of 10.59 per cent. The spread between low and high is USD 93.6 billion, which is 59 per cent of the base year: for a market whose unit economics are this levered to two variables, that is the honest width of the answer.

The base year itself is derived rather than observed, and the derivation is checkable. US specialty drug spending was approximately USD 263 billion in 2024 — 54 per cent of pharmaceutical spending, up from 47 per cent in 2019 — on the Tufts Medical Center analysis of FDA specialty drug approvals. Applying the 55 per cent orphan share of specialty drug-indication pairs gives USD 144.65 billion for 2024, and growing that at 9.0 per cent gives the USD 157.7 billion base. A reader who rejects either input can rebuild the forecast from their own, which is the point of publishing the chain.

Technology & Innovation

Technology and innovation: the route of administration is the price

The 2025 cohort was 34 new molecular entities and 12 novel biologics, of which 20 (43.5 per cent) were first-in-class — mechanisms of action different from anything already approved. That is a technology story. It is also a pricing story, because in orphan drugs the delivery technology predicts the price more reliably than the science does.

The route-of-administration price gradient

Those averages come from 108 non-oncology orphan launches between 2015 and 2024 (ISPOR 2025). The gradient is not a quirk: IV and health-care-professional-administered products carry buy-and-bill economics, site-of-care costs, infusion infrastructure and a services component that the price has to cover, while an oral solid is dispensed through a specialty pharmacy with a fraction of the overhead. What matters for the 2025 cohort is its mix.

Twelve orals and eleven injectables — and how that mix pushes the cohort’s price down

Of the twenty-three orphan approvals: twelve are oral solids (Ekterly, Sephience, Palsonify, Myqorzo, Jascayd, Komzifti, Modeyso, Hyrnuo, Ibtrozi, Wayrilz, Avmapki Fakzynja, Gomekli) and eleven are injectables, infusions or powders for reconstitution (Andembry, Dawnzera, Imaavy, Qfitlia, Kygevvi, Forzinity, penpulimab, Yartemlea, Grafapex, Lynozyfic, Redemplo). On the historical averages that mix sits closer to the USD 314,000 oral point than to the USD 517,000 IV point. The 2025 median net launch price of USD 257,000 — 2 per cent below 2024, and USD 293,000 on a list-price basis per the ICER and West Health series — is consistent with a cohort that shifted toward oral modalities, which means part of what looks like price discipline may simply be product mix. That reading is strengthened by the same series’ own mix table, which reports gene and cell therapies, biologics, orphan products and ultra-rare drugs all falling as a share of 2025 approvals. This report states the mix effect as a hypothesis the data support but do not prove, because ICER does not publish a route-of-administration breakdown for 2025.

The first-in-class share and what it is worth

Twenty of forty-six novel approvals (43.5 per cent) were first-in-class, and the mechanism premium sits with the position that novelty buys: first-in-indication products carried an expected USD 254,280 above later entrants across 108 non-oncology orphan launches, falling to USD 82,813 once ultra-rare products are excluded. Mechanism novelty is therefore a pricing asset principally in the smallest populations and a marketing asset everywhere else.

Small trials, thin characterisation

The technology that makes 12-patient and 78-patient approvals possible is also the technology that limits what those approvals know. A randomised programme of 12 patients can establish a direction of effect on a well-chosen endpoint; it cannot establish a safety profile across a population, and it cannot detect uncommon events. That is why 11 of 46 (23.9 per cent) novel approvals came through accelerated approval, where the FDA requires post-approval studies to confirm clinical benefit and may withdraw an approval if benefit is not confirmed. In a market priced at USD 257,000 a patient-year, the confirmatory trial is not an academic obligation — it is the asset’s largest single binary risk, and it is why accelerated approval functions as a financing instrument as much as a regulatory one.

Where the technology curve is heading in this cohort

• Biomarker-defined oncology is now the default. Hyrnuo (HER2 TKD), Ibtrozi (ROS1), Zegfrovy (EGFR exon 20), Emrelis (c-Met), Inluriyo (ESR1), penpulimab (NPC) — six of the year’s approvals require an FDA-approved companion test or a defined alteration. Diagnosis is upstream of the market, which is why the diagnostic tests and clinical laboratory services layers price with it rather than beneath it.
• Rare metabolic disease is where the small-programme model is most extreme. Kygevvi (78 patients), Forzinity (12), Sephience (98), Redemplo (75) — four approvals averaging 65.75 patients each, all targeting substrates rather than symptoms.
• Oral alternatives to injectable chronic therapy are the quiet theme. Palsonify against injectable somatostatin analogues in acromegaly; Myqorzo against beta-blockers and disopyramide in obstructive hypertrophic cardiomyopathy; Wayrilz against intravenous immunoglobulin and anti-D in immune thrombocytopenia; Ekterly against injectable icatibant and plasma-derived C1-inhibitor in acute HAE. Each is a convenience-and-price play inside an established class rather than a new class, and each will be priced against a comparator that payers already know how to buy.

The technology conclusion is uncomfortable for anyone who reads approvals as progress: in 2025 the cohort’s most important technical attribute was not the mechanism. It was the pill.

Market Risk

Market risk: five things that break this forecast

The base case grows the US orphan market from USD 157.7 billion in 2025 to USD 224.9 billion in 2033 at 4.54 per cent. That is a modest number built on modest drivers, and it is exposed at five specific points. Each is stated with the observation that would falsify the treatment here.

Risk 1 — the price ceiling is now visible, and it moved down last year

The median annual net launch price was USD 257,000 in 2025, down 2 per cent on 2024 — the first decline in the ICER and West Health series, after a 35 per cent rise from USD 190,000 in 2022 on the same source’s series. A single year is not a trend. But this report’s base case assumes net price growth of 2.0 per cent a year, and the three-year rate it is replacing was 10.59 per cent. If price growth simply reverts to zero, the market lands at USD 170.7 billion in 2033 (1.00 per cent), not USD 224.9 billion. Falsifier: a 2026 median net launch price above USD 270,000 — more than 5 per cent growth — would show the 2025 dip was mix and noise.

Risk 2 — the fill rate is the largest single destroyer of value in the model

Only about one third of outpatient prescriptions filled within 30 days in the first post-approval year; Medicare fill was 20 per cent with 58 per cent non-coverage rejection. At the median net price that is USD 85,658 of revenue per prescription written against USD 257,000 per filled patient-year. Nothing in the price or regulatory outlook improves this, and the cohort’s disease mix tilts toward Medicare-age populations — acromegaly, generalised myasthenia gravis, idiopathic pulmonary fibrosis, multiple myeloma, obstructive hypertrophic cardiomyopathy. Falsifier: a published 2026 cohort showing commercial fill above 60 per cent and Medicare above 40 per cent would materially raise every path in this report.

Risk 3 — the evidence base is thin, and the confirmatory obligation is binary

Median pivotal programme of 114 patients; nine of twenty-three under 100; 11 of 46 novel approvals through accelerated approval, where the FDA requires post-approval confirmation and may withdraw an approval if benefit is not confirmed. A withdrawal in a 12-patient or 78-patient indication removes the entire revenue line, not a share of it — which is why the ultra-rare end of this cohort, populations of the malignant infantile osteopetrosis order, carries more concentration risk per approval than any large programme in the year. Falsifier: a confirmed withdrawal from the 2025 cohort would validate the risk; a clean confirmation record across the next three years would argue that the small-programme model is more robust than this report assumes.

Risk 4 — the negotiation exclusion is a statute, and statutes get amended

Section 71203 of Public Law 119-21 is the widest single support under the terminal value of an orphan asset, and it is barely a year old in guidance terms. It could be narrowed by a later Congress, by a court, or by an administration reading the words all approved indications are for one or more rare diseases more strictly than the current guidance does. The CMS final guidance published 30 September 2025 complicates the position further, because it still frames the test around a single rare-disease designation and records CMS declining to read the statute more broadly. On the face of the two documents, the statute is already ahead of the guidance — which means part of this risk is not amendment at all, but ordinary administrative interpretation. Falsifier: a CMS interpretation or court decision requiring the exclusion to be tested indication by indication would remove the strategic value of the stacked rare label and reset the follow-on calculus in this report; conversely, guidance that adopts the amended statutory reading in full would remove the interpretation risk identified here and strengthen the base case.

Risk 5 — revenue concentration inside a fragmented sponsor base

Twenty-three approvals came from roughly twenty-three sponsors, but only two of the twenty-three programmes (Jascayd at 1,322 patients, Grafapex at 570) have an evidence base large enough to support a broad commercial footprint — and both sit in classes with existing incumbents (idiopathic pulmonary fibrosis; allogeneic transplant preparative regimens). A market that depends on eight oncology programmes and three HAE programmes for its incremental growth is exposed to class crowding: three NSCLC approvals in a single year, three HAE mechanisms within nine weeks. Falsifier: concentrated class-level revenue decline in NSCLC or HAE among 2025 entrants would show that the approval count overstates the market’s capacity to absorb new products.

Two risks this report deliberately does not quantify

Supply and tariff exposure. Orphan products are disproportionately biologics — 12 of 46 novel approvals in 2025 were original BLAs, and the orphan cohort skews to injectables and infusions — which means single-site manufacturing, cold chain and cross-border release testing. This report does not carry a tariff or reshoring scenario because the policy is not settled enough to score.

The evidence-to-price relationship under scrutiny. A 114-patient median and a USD 257,000 median price are, taken together, an argument that payers and policymakers will eventually contest. The 2025 net-price decline may be the first sign of that contest. It is flagged as a direction of travel, not measured as a cost.

What would prove this report wrong, in one line each

• A 2026 median net launch price above USD 270,000 — the price-stall thesis fails.
• Commercial fill above 60 per cent in the 2026 cohort — the access thesis is overstated.
• Any disclosed acquisition of a single-asset orphan sponsor at a price that implies distribution, not science, is the scarce asset — the investment chapter’s inference is confirmed rather than falsified, and the direction of the market changes.
• A narrowing of section 71203, or guidance that reads it more narrowly than the statute — the terminal value of every mature orphan asset in this report falls.

Regulatory Landscape

Regulatory landscape: the designation, the clock and Public Law 119-21

Three regulatory instruments set the boundaries of this market. The Orphan Drug Act sets the incentive. The user-fee and expedited-pathway stack sets the speed. Public Law 119-21 sets the terminal value. The 2025 record is unusually clean on all three.

1. The designation itself

Orphan designation applies to drugs intended to treat, diagnose or prevent diseases affecting fewer than 200,000 people in the United States. It carries seven years of market exclusivity for the orphan indication, a waiver of the prescription drug user fee, a tax credit for qualified clinical testing, and protocol assistance during development — all four set out on the FDA’s own orphan drug designation page. In 2025, 23 of 46 novel approvals (50.0 per cent) held the designation, counted against CDER’s own 2025 approval list.

One caveat matters for anyone comparing across sources. The FDA states plainly that not all drugs for rare diseases receive orphan drug designation. So a count of designated approvals understates the rare-disease share of the pipeline by an unknown margin: Reuters’ analysis of 2024 found 72 per cent of that year’s new drugs were for orphan diseases, against CDER’s 50 per cent with orphan designation in 2025. Both figures are defensible; they answer different questions. This report uses designation because designation is the thing that carries the exclusivity and the negotiation exclusion.

2. The approval machine is saturated

The ten-year series puts 46 in context: 22 (2016), 46 (2017), 59 (2018), 48 (2019), 53 (2020), 50 (2021), 37 (2022), 54 (2023), 50 (2024), 46 (2025) — a mean of 46.5, and above the 38-a-year average since 2007. The 2025 total is 8.0 per cent below 2024’s 50 and indistinguishable from the ten-year average. There is no approval-cycle story here; the count is steady, and that steadiness is what makes the orphan share the interesting variable.

3. Enforcement is more transparent, and that changes the risk

CDER issued 19 complete response letters against 18 novel drugs in 2025, and from September 2025 began making those letters available to the public. A rejection rate of roughly one in five at the application level, published, is a materially different information environment from the one that existed before — for investors pricing regulatory risk, and for competitors reading a rival’s deficiency.

4. Public Law 119-21, section 71203: the widest change in the record

The Medicare Drug Price Negotiation Program’s orphan exclusion was previously narrow. A drug qualified only if it was designated for one rare disease or condition and all of its approved indications were for that disease. The Working Families Tax Cuts Act (Public Law 119-21), section 71203 — titled, in the statute’s own words, expanding and clarifying the exclusion for orphan drugs under the Drug Price Negotiation Program — replaced that test: a product is excluded if it is designated for one or more rare diseases and all of its approved indications are for one or more such rare diseases.

What CMS has and has not done with it is the part to read carefully, because the guidance and the statute are not saying quite the same thing yet. The final guidance for the initial price applicability year 2028, published 30 September 2025, still frames the exclusion around a product designated for a single rare disease and approved only for indications within it. The comment record the guidance publishes shows respondents pressing CMS to extend the exclusion to products with several rare-disease designations that are approved only within one of them — and CMS replying that it cannot amend the statutory requirement. On the face of the document, then, the amended statute is broader than the policy the guidance articulates, and the operative question for a stacked rare label is left to a later guidance cycle or to litigation. This report treats that question as open rather than assuming the sponsor-favourable reading, because the terminal value of a multi-indication orphan asset depends entirely on which reading survives. It is also the single sharpest difference between the price floor described in the investment chapter and the statute as drafted.

What the change means commercially, stated plainly:

• A single-indication orphan product no longer gains anything by staying single-indication, and no longer loses its exclusion by adding a second rare indication.
• The rational strategy shifts from broadening into common disease to stacking rare-disease indications — each new all-rare label expands revenue and re-affirms the exclusion.
• The value of a mature orphan asset is now partly a function of statutory drafting risk rather than only of patent life, which is a new category of risk for a market that historically priced regulatory risk as approval risk.

5. What the regime does not cover

Two gaps are worth naming. First, designation is a US instrument; the 2025 cohort’s US-first share of 69.6 per cent means roughly three in ten were approved elsewhere first, so the US exclusivity clock was not the binding one for a substantial minority. Second, the negotiation exclusion protects price only inside Medicare. The commercial book is where the 51 per cent fill rate sits, and no part of this regulatory stack addresses the non-coverage rejection rates that cost the cohort more revenue than any price negotiation will.

6. The adjacent regulatory facts a reader should hold

CDER approved 123 products in total in 2025, including non-novel new dosage forms and formulations, and 18 biosimilars for 10 reference products — bringing the biosimilar total since 2015 to 81 products across 20 reference products. Combined with CBER, novel approvals for the year were 58. The biosimilar layer matters to this market indirectly: every biosimilar approval is a price deflator in a class that an orphan product may later want to price against.